ClinicalTrials.gg
CompletedNCT04282980Updated Mar 3, 2025Results posted

A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)

A Phase 2 interventional study of DCC-2618 in Gastrointestinal Stromal Tumors, sponsored by Zai Lab (Shanghai) Co., Ltd.. Completed at 9 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-03.

Sponsored by Zai Lab (Shanghai) Co., Ltd. (part of Zai Lab Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 69 studies in Gastrointestinal Stromal Tumors with a site in China — 24 open to participants now, 28 under way, 4 of them phase 3. Gastrointestinal Stromal Tumors · China.

Enrollment
39th of 46
39 · median 100
Started
2020
with 6 others
Phase 2
11 of 69
5 open now
Registered
26th of 69
by date

Among the 69 studies in Gastrointestinal Stromal Tumors with a site in China, this one is the 39th largest by enrollment of the 46 interventional ones that give a count, is one of 7 that started in 2020, is one of 11 in phase 2, and was the 26th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

24 of the 69 studies in Gastrointestinal Stromal Tumors with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Gastrointestinal Stromal Tumors with a site in China, or all of them as a file.
02

Study summary

The primary objective of this trial is to evaluate the progress free survival (PFS) of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have progressed with prior anticancer therapies based on independent radiologic review.

Read the detailed description

The primary objective of this trial is to evaluate the progress free survival (PFS) of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have progressed with prior anticancer therapies based on independent radiologic review. This study enrolled 39 subjects of 9 sites in China mainland, and all enrolled subjects received DCC-2618 after enrollment as treatment.

The study used EDC to collect patient data and IRT system for patient randomization, using Imaging Endpoints as the central image to evaluate the PFS.

03

Conditions studied

  • Gastrointestinal Stromal Tumors

Keywords

  • Gastrointestinal Stromal Tumors,GIST,DCC-2618,Ripretinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥18 years of age.
  • Patients with advanced gastrointestinal stromal tumors.
  • Subjects who have progressed or documented intolerance after previous treatments.
  • Sign , understand the Protocol and could follow the Protocol.
  • The subject had at least one .
  • Adequate organ function and bone marrow reserve

Exclusion criteria

Exclusion Criteria:

  • Treatment with anticancer therapy, including therapy, or investigational procedures within 14 days or 5 x the half-life (whichever is longer) prior to the first dose of investigational drug.
  • Prior treatment with DCC-2618.
  • Previously or currently has an additional that is progressing or required active treatment, which may interfere with the safety or efficacy evaluation of DCC-2618.
  • Patient has known active central nervous system .
  • class II - IV heart disease, active ischemia or any other uncontrolled cardiac condition.
  • Arterial thrombotic or embolic events within 6 months before the first dose of investigational drug.
  • Venous thrombotic events within 3 months before the first dose of investigational drug.
  • 12-lead (ECG) demonstrating corrected by Fridericia's formula >450 ms in males or >470 ms in females at screening or history of long QT interval syndrome.
  • (LVEF) \<50% at screening.
  • Use of known substrates or inhibitors of breast cancer resistance protein (BCRP) transporters within 14 days or 5 x the half-life (whichever is longer) prior to the first dose of investigational drug.
  • Major surgeries within 4 weeks of the first dose of investigational drug.
  • Any other comorbidities, which in the judgment of the investigator, could compromise compliance with the protocol, interfere with interpretation of the study results, or predispose the patient to safety risks.
  • Active viral infections.
  • If female, the patient is pregnant or lactating, or plans to become pregnant during the study treatment period.
  • Known allergy or to any component of the investigational drug.
  • Gastrointestinal abnormalities.
  • Any active hemorrhages, excluding hemorrhoids or gum bleeding.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    DCC-2618

    DCC-2618 drug is 50mg per tablet, 150mg once a day, with 28 days as a treatment cycle.

    Drug: DCC-2618

Interventions

  • Oral kinase inhibitor

    Also known as: Ripretinib

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Progression-Free Survival (PFS) is defined as the time from the first dose of study drug to the first occurrence of disease progression based on independent radiology review or death due to any cause (whichever occurred first).

    Time frame: Approximately 10 months since the first subject enrolled.

Secondary outcomes

  1. Objective Response Rate (ORR)

    The objective response rate (ORR) is defined as the percentage of participants who achieved confirmed complete response (CR) or partial responses (PR) based on independent radiology review.

    Time frame: Approximately 15 months since the first subject enrolled.

  2. Overall Survival (OS)

    Overall survival (OS) is defined as the time from the first dose of study drug to all-cause death.

    Time frame: Approximately 28 months since the first subject enrolled.

  3. Time to Best Response (TBR)

    Time to Best Response(TBR) based on independent radiology review is defined as the duration from the date of the first dose of the investigational drug to the date of confirming the best response.

    Time frame: Approximately 15 months since the first subject enrolled.

  4. Disease Control Rate (DCR) (Confirmed CR + Confirmed PR + SD) for 12 Weeks

    Disease control rate (DCR) based on independent radiology review (confirmed CR + confirmed PR + SD for 12 weeks)

    Time frame: Approximately 15 months since the first subject enrolled.

07

Results

Posted Mar 3, 2025

Participant flow

Between April 2020 and August 2020, 39 patients were enrolled, and all received at least one dose of study drug.

Participant flow — Overall Study
MilestoneDCC-2618
Started39
Completed20
Not completed19
Withdrew: Remained on treatment6
Withdrew: Survival follow-up11
Withdrew: Withdrawal of informed consent1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryProgression-Free Survival (PFS)

Progression-Free Survival (PFS) is defined as the time from the first dose of study drug to the first occurrence of disease progression based on independent radiology review or death due to any cause (whichever occurred first).

Time frame:
Approximately 10 months since the first subject enrolled.
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsDCC-2618
Progression-Free Survival (PFS)6.44 (2.89 to 8.31)
SecondaryObjective Response Rate (ORR)

The objective response rate (ORR) is defined as the percentage of participants who achieved confirmed complete response (CR) or partial responses (PR) based on independent radiology review.

Time frame:
Approximately 15 months since the first subject enrolled.
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsDCC-2618
Objective Response Rate (ORR)8
SecondaryOverall Survival (OS)

Overall survival (OS) is defined as the time from the first dose of study drug to all-cause death.

Time frame:
Approximately 28 months since the first subject enrolled.
Reported as:
Median · months
Overall Survival (OS)
monthsDCC-2618
Overall Survival (OS)25.56 (11.73 to NA)
SecondaryTime to Best Response (TBR)

Time to Best Response(TBR) based on independent radiology review is defined as the duration from the date of the first dose of the investigational drug to the date of confirming the best response.

Time frame:
Approximately 15 months since the first subject enrolled.
Reported as:
Median · months
Time to Best Response (TBR)
monthsDCC-2618
Time to Best Response (TBR)2.25 (1.0 to 11.9)
SecondaryDisease Control Rate (DCR) (Confirmed CR + Confirmed PR + SD) for 12 Weeks

Disease control rate (DCR) based on independent radiology review (confirmed CR + confirmed PR + SD for 12 weeks)

Time frame:
Approximately 15 months since the first subject enrolled.
Reported as:
Count of participants · Participants
Disease Control Rate (DCR) (Confirmed CR + Confirmed PR + SD) for 12 Weeks
ParticipantsDCC-2618
Disease Control Rate (DCR) (Confirmed CR + Confirmed PR + SD) for 12 Weeks20

Adverse events

Collected over From the date of the first dose of study treatment up to 30 days following study treatment discontinuation. Up to approximately 28 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DCC-261820/39 (51.3%)10/39 (25.6%)39/39 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventDCC-2618
Gastrointestinal haemorrhageGastrointestinal disorders3/39
AnaemiaBlood and lymphatic system disorders2/39
PyrexiaGeneral disorders1/39
Cardiac dysfunctionCardiac disorders1/39
Acute kidney injuryRenal and urinary disorders1/39
Abdominal pain upperGastrointestinal disorders1/39
Acute myocardiac infarctionCardiac disorders1/39
PneumoniaInfections and infestations1/39
Inra-abdomina fluid collectionGastrointestinal disorders1/39
Aabdominal painGastrointestinal disorders1/39
Most frequent other events
Showing 10 of 84
Most frequent other events
EventDCC-2618
AnaemiaBlood and lymphatic system disorders26/39
AlopeciaSkin and subcutaneous tissue disorders17/39
AstheniaGeneral disorders13/39
Bilirubin conjugated increasedInvestigations13/39
Blood bilirubin increasedInvestigations13/39
Weight decreasedInvestigations10/39
Abdominal distensionGastrointestinal disorders9/39
HypokalaemiaMetabolism and nutrition disorders9/39
MyalgiaMusculoskeletal and connective tissue disorders9/39
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders9/39

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)DCC-2618
<=18 years0
Between 18 and 65 years32
>=65 years7
Age, Continuous
Age, Continuous(years)DCC-2618
Median55.1 (36.8 to 73.6)
Sex: Female, Male
Sex: Female, Male(Participants)DCC-2618
Female12
Male27
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DCC-2618
American Indian or Alaska Native0
Asian39
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)DCC-2618
China39
ECOG performance status
ECOG performance status(Participants)DCC-2618
07
128
24
08

Study locations

9 sites
  • Beijing Cancer Hospital
    Beijing, Beijing, China
  • Chinese People's Liberation Army General Hospital
    Beijing, Beijing, China
  • Union Medical College Hospital, Chongqing Medical University
    Chongqing, Chongqing, China
  • Union Medical College Hospital, Fujian Medical University
    Fuzhou, Fujian, China
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
  • The Sixth Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
  • Fudan University Cancer Hospital
    Shanghai, Shanghai, China
  • Renji Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Feb 2021, 10 months.

Results were first posted in Mar 2025, 4 years after primary completion.

Of 47 phase 2 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 92. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2020
First posted
Feb 25, 2020
StartActual
Apr 23, 2020
Primary completionActual
Feb 26, 2021
CompletionActual
Aug 23, 2022
Results first posted
Mar 3, 2025
Last update
Mar 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04282980
Responsible party
Sponsor
First posted
Feb 25, 2020
Start date
Apr 23, 2020
Primary completion
Feb 26, 2021
Completion
Aug 23, 2022
Results posted
Mar 3, 2025
Last update
Mar 3, 2025

Study contacts

Zai Lab
study director · Zai Lab (Shanghai) Co., Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ripretinib

Start the discussion